Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Benign prostatic hyperplasia (BPH) is a noncancerous urinary disorder that is common in older adult men; however, its underlying mechanisms remain unclear. Fenugreek has some biological effects, including hyperglycemia regulation, immune response modulation, and anti-cancer properties; In this study, we investigated the ameliorative effects of fenugreek seed extract (Forceterone [FCT]) in a testosterone propionate (TP)-induced BPH animal model and its mechanisms in BPH-1 human prostate epithelial cells. Sprague Dawley (SD) rats were injected subcutaneously with TP (3 mg/kg) for 8 weeks to induce BPH while FCT was administered orally at 25, 50, and 100 mg/kg. In addition, BPH-1 cells were used to evaluate the inhibitory effects on cell proliferation and examine inflammatory cytokine expression. Treating rats with FCT decreased prostate weight, dihydrotestosterone (DHT) level, and proliferating cell nuclear antigen (PCNA) expression in the prostate. Furthermore, it decreased androgen receptor (AR), 5α-reductase 2, B-cell lymphoma 2 (Bcl-2), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and NF-κB expression in vitro and in vivo and increased Bcl-2-associated X protein (Bax) expression. FCT also inhibited cell proliferation dose dependently in BPH-1 cells. These findings showed the potential use of FCT as an alternative treatment for BPH.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11818512PMC
http://dx.doi.org/10.3390/ijms26031261DOI Listing

Publication Analysis

Top Keywords

benign prostatic
8
prostatic hyperplasia
8
bph-1 cells
8
cell proliferation
8
fenugreek extract
4
extract testosterone
4
testosterone propionate-induced
4
propionate-induced benign
4
hyperplasia benign
4
bph
4

Similar Publications

Purpose: Men with lower urinary tract symptoms (LUTS) from benign prostatic hyperplasia (BPH) often experience erectile dysfunction (ED). While transurethral resection of the prostate (TURP) can improve ED, new-onset ED remains a concern. This study compares monopolar (M-TURP) and bipolar (B-TURP) techniques, with a subgroup analysis based on phosphodiesterase-5 inhibitor (PDE5i) use.

View Article and Find Full Text PDF

Alantolactone prevents testosterone-induced benign prostatic hyperplasia in rats via modulation of PTEN/PI3K/AKT axis.

Biochem Biophys Res Commun

September 2025

Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah, 21589, Saudi Arabia. Electronic address:

Current treatment options for benign prostatic hyperplasia (BPH) suffer intolerable adverse effects. The goal of this investigation was to evaluate the possible protective effects of alantolactone (ALA) in testosterone (TEST)-induced BPH in rats. Wistar rats were grouped into 5 batches namely; Control, ALA (10 mg/kg), TEST, TEST + ALA (5 mg/kg) and TEST + ALA (10 mg/kg).

View Article and Find Full Text PDF

Benign prostatic hyperplasia (BPH) presents a significant clinical challenge, with conventional therapies carrying substantial risks, including urinary retention, sexual dysfunction, and prolonged recovery. To address the urgent need for safer, ultra-minimally invasive alternatives, we developed a sonosensitizing nanoplatform using copper-manganese-doped mesoporous silica nanoparticles (Cu-Mn@SiO) for ultrasound-induced sonodynamic therapy (SDT). Here, we demonstrate that this innovative strategy provides highly effective and precisely targeted therapy for BPH.

View Article and Find Full Text PDF

Objective: To explore the role of prostate health index (PHI) and its derivatives for early screening in patients with PI-RADS score 3 and prostate-specific antigen (PSA) levels of 4-20 μg/L.

Methods: Clinical data of 203 patients with a score of 3 on the PI-RADS v2.1 scoring system who underwent ultrasound-guided transperineal prostate aspiration biopsy from April 2021 to April 2024 from Provincial Hospital of Shandong First Medical University, Qilu Hospital of Shandong University and Weifang People's Hospital were collected.

View Article and Find Full Text PDF

Objective: To analyze the symptoms, diagnosis and treatment of upper urinary tract calculi patients combined with mild and moderate benign prostatic hyperplasia (BPH) after ureteral stent implantation. Methods: One hundred and six BPH patients who were hospitalized for upper urinary tract calculi and had ureteral stents retained from January 2019 to December 2022 were selected and divided into 2 weeks group and 4 weeks group according to the time of removal of ureteral stents after surgery. Their general clinical data were analyzed and compared.

View Article and Find Full Text PDF